Yoshitaka Hashimoto1, Muhei Tanaka1, Hiroshi Okada2, Takafumi Senmaru1, Masahide Hamaguchi1, Mai Asano1, Masahiro Yamazaki1, Yohei Oda1, Goji Hasegawa2, Hitoshi Toda3, Naoto Nakamura1, Michiaki Fukui4. 1. Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; 2. Division of Metabolism, Nephrology and Rheumatology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan; and. 3. Department of Internal Medicine, Oike Clinic, Kyoto, Japan. 4. Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; sayarinapm@hotmail.com.
Abstract
BACKGROUND AND OBJECTIVES: Metabolically healthy obesity (MHO) is a unique obesity phenotype that apparently protects people from the metabolic complications of obesity. The association between MHO phenotype and incident CKD is unclear. Thus, this study investigated the association between MHO phenotype and incident CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 3136 Japanese participants were enrolled in an 8-year follow-up cohort study in 2001. Metabolically healthy status was assessed by common clinical markers: BP, triglycerides, HDL cholesterol, and fasting plasma glucose concentrations. Body mass index ≥25.0 kg/m(2) was defined as obesity. CKD was defined by proteinuria or eGFR of <60 ml/min per 1.73 m(2). To calculate the odds ratio for incident CKD, logistic regression analyses were performed. RESULTS: The crude incidence proportions of CKD were 2.6% (56 of 2122 participants) in participants with the metabolically healthy nonobesity phenotype, 2.6% (8 of 302) in those with the MHO phenotype, 6.7% (30 of 445) in those with the metabolically abnormal nonobesity phenotype, and 10.9% (29 of 267) in those with the metabolically abnormal obesity phenotype. Compared with metabolically healthy nonobesity phenotype, the odds ratios for incident CKD were 0.83 (95% confidence interval [95% CI], 0.36 to 1.72; P=0.64) for MHO, 1.44 (95% CI, 0.80 to 2.57; P=0.22) for metabolically abnormal nonobesity, and 2.80 (95% CI, 1.45 to 5.35; P=0.02) for metabolically abnormal obesity phenotype after adjustment for confounders, including age, sex, smoking statues, alcohol use, creatinine, uric acid, systolic BP, HDL cholesterol, and impaired fasting glucose or diabetes. CONCLUSION: MHO phenotype was not associated with higher risk of incident CKD.
BACKGROUND AND OBJECTIVES: Metabolically healthy obesity (MHO) is a unique obesity phenotype that apparently protects people from the metabolic complications of obesity. The association between MHO phenotype and incident CKD is unclear. Thus, this study investigated the association between MHO phenotype and incident CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 3136 Japanese participants were enrolled in an 8-year follow-up cohort study in 2001. Metabolically healthy status was assessed by common clinical markers: BP, triglycerides, HDL cholesterol, and fasting plasma glucose concentrations. Body mass index ≥25.0 kg/m(2) was defined as obesity. CKD was defined by proteinuria or eGFR of <60 ml/min per 1.73 m(2). To calculate the odds ratio for incident CKD, logistic regression analyses were performed. RESULTS: The crude incidence proportions of CKD were 2.6% (56 of 2122 participants) in participants with the metabolically healthy nonobesity phenotype, 2.6% (8 of 302) in those with the MHO phenotype, 6.7% (30 of 445) in those with the metabolically abnormal nonobesity phenotype, and 10.9% (29 of 267) in those with the metabolically abnormal obesity phenotype. Compared with metabolically healthy nonobesity phenotype, the odds ratios for incident CKD were 0.83 (95% confidence interval [95% CI], 0.36 to 1.72; P=0.64) for MHO, 1.44 (95% CI, 0.80 to 2.57; P=0.22) for metabolically abnormal nonobesity, and 2.80 (95% CI, 1.45 to 5.35; P=0.02) for metabolically abnormal obesity phenotype after adjustment for confounders, including age, sex, smoking statues, alcohol use, creatinine, uric acid, systolic BP, HDL cholesterol, and impaired fasting glucose or diabetes. CONCLUSION: MHO phenotype was not associated with higher risk of incident CKD.
Authors: M Brochu; A Tchernof; I J Dionne; C K Sites; G H Eltabbakh; E A Sims; E T Poehlman Journal: J Clin Endocrinol Metab Date: 2001-03 Impact factor: 5.958
Authors: Ron T Gansevoort; Ricardo Correa-Rotter; Brenda R Hemmelgarn; Tazeen H Jafar; Hiddo J Lambers Heerspink; Johannes F Mann; Kunihiro Matsushita; Chi Pang Wen Journal: Lancet Date: 2013-05-31 Impact factor: 79.321
Authors: Lara L Roberson; Ehimen C Aneni; Wasim Maziak; Arthur Agatston; Theodore Feldman; Maribeth Rouseff; Thinh Tran; Michael J Blaha; Raul D Santos; Andrei Sposito; Mouaz H Al-Mallah; Ron Blankstein; Matthew J Budoff; Khurram Nasir Journal: BMC Public Health Date: 2014-01-08 Impact factor: 3.295
Authors: Hak Joo Lee; Meenalakshmi M Mariappan; Luke Norton; Terry Bakewell; Denis Feliers; Sae Byeol Oh; Andrew Donati; Cherubina S Rubannelsonkumar; Manjeri A Venkatachalam; Stephen E Harris; Isabelle Rubera; Michel Tauc; Goutam Ghosh Choudhury; C Ronald Kahn; Kumar Sharma; Ralph A DeFronzo; Balakuntalam S Kasinath Journal: JCI Insight Date: 2021-02-08